Twice daily treatment with Valtrex® (valacyclovir HCl) caplets is effective in suppressing genital herpes recurrences in HIV-infected patients, according to data presented at the Infectious Diseases Society of America annual meeting. After six months, the proportion of patients recurrence-free was 80 percent in those receiving Valtrex 500 mg twice daily, compared to only 38 percent of those receiving placebo.
“Many people who are HIV-positive also suffer from genital herpes and will be pleased to know they can suppress their genital herpes outbreaks,” said Timothy Schacker, M.D., Associate Professor of Medicine, University of Minnesota. “This is important information for people who have to deal with both genital herpes and HIV.”
In the study of 293 HIV-infected participants, those receiving Valtrex experienced a delay in the time to first genital herpes recurrence as well as a delay in the time to first oral herpes outbreak when compared to placebo. At the end of the six-month study period, researchers noted no change in HIV-1 RNA levels present in the blood for patients treated with either Valtrex or placebo.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!